Collaborative Arrangements - Kymera and Other In-License Agreements (Details) $ in Millions |
1 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
|
May 31, 2019
USD ($)
target
|
Dec. 31, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
Dec. 31, 2017
USD ($)
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Investment in collaborative partner, pursuant to convertible loan agreement | $ 63.3 | $ 46.9 | $ 8.7 | |
| Kymera Therapeutics | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Up-front payment | $ 50.0 | |||
| Right to license, number of targets (up to) | target | 6 | |||
| Collaborative arrangement development and regulatory potential milestone payments maximum | $ 170.0 | |||
| Investment in collaborative partner, pursuant to convertible loan agreement | $ 20.0 | |||
| Molecular Templates, Inc | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Up-front payment | $ 25.9 | |||
| Arbor | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Up-front payment | $ 30.0 | |||